Allogene Therapeutics Inc (ALLO)
1.4500 x 80 1.5500 x 5
Pre-market by (Cboe BZX)
1.5500 -0.0100 (-0.64%) 03/28/25 [NASDAQ]
1.4500 x 80 1.5500 x 5
Pre-market 1.5400 -0.0100 (-0.65%) 05:21 ET
for Fri, Mar 28th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2019 | 12-2018 | 12-2017 | 12-2006 | |
Assets | ||||
Current Assets | ||||
Cash & Cash Equivalents | 175,126 | 92,432 | N/A | N/A |
Marketable Securities | 355,407 | 366,952 | N/A | N/A |
TOTAL | $544,576 | $467,982 | $N/A | $N/A |
Non-Current Assets | ||||
PPE Net | 56,449 | 8,595 | N/A | N/A |
Investments And Advances | 63,214 | 261,966 | 0 | 0 |
Intangibles | 151 | 754 | 0 | 0 |
Other Non-Current Assets | 53,412 | 34,558 | 0 | 0 |
TOTAL | $173,226 | $305,873 | $N/A | $N/A |
Total Assets | $717,802 | $773,855 | $N/A | $N/A |
Liabilities | ||||
Current Liabilities | ||||
Accounts payable and accrued liabilities | 9,250 | 12,338 | 0 | 0 |
Accrued Expenses | 23,829 | 17,121 | 2 | N/A |
TOTAL | $33,079 | $29,459 | $2 | $N/A |
Non-Current Liabilities | ||||
aiOther Non-Current Liabilities | 55,700 | 41,232 | 0 | 0 |
TOTAL | $55,700 | $41,232 | $N/A | $N/A |
Total Liabilities | $88,779 | $70,691 | $2 | $N/A |
Shareholders' Equity | ||||
Shares Outstanding, K | 124,907 | 121,483 | N/A | N/A |
Common Shares | 124 | 121 | 26 | N/A |
Retained earnings | -396,122 | -211,528 | -23 | N/A |
Other shareholders' equity | 1,145 | 306 | -5 | 0 |
TOTAL | $629,023 | $703,164 | $-2 | $N/A |
Total Liabilities And Equity | $717,802 | $773,855 | $0 | $0 |